ClinicalTrials.gg
Not yet recruitingNCT07177235Updated Sep 16, 2025

Ketamine for the Treatment of Refractory Status Epilepticus

A Phase 4 interventional study of Ketamine and Midazolam in Refractory Status Epilepticus, sponsored by Thomas Jefferson University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Thomas Jefferson University · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Status Epilepticus with a site in United States — 13 open to participants now, 13 under way, 2 of them phase 3. Status Epilepticus · United States.

Planned enrollment
14th of 30
50 · median 35
Started
2025
with 2 others
Phase 4
2 of 41
1 open now
Primary completion
2027-07
later than 4 of 12 live
Registered
38th of 41
by date

Among the 41 studies in Status Epilepticus with a site in United States, this one is the 14th largest by planned enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2025, is one of 2 in phase 4, reaches primary completion later than 4 of the 12 other live ones, and was the 38th registered.

Status Epilepticus

124 studies on the registry are indexed under Status Epilepticus; 37 are open to participants now.

Browse Status Epilepticus studies →

Open to participants now

13 of the 41 studies in Status Epilepticus with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Status Epilepticus studies recruiting now, 16 (55%) set no upper age limit and 8 (28%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Status Epilepticus with a site in United States, or all of them as a file.
02

Study summary

This pilot feasibility study aims to examine how the timing of ketamine introduction as a third-line anti-seizure medication infusion relates to seizure cessation in patients with refractory status epilepticus (RSE).

Read the detailed description

Patients admitted to the Jefferson Neurological Intensive Care Unit with seizures or status epilepticus will be screened for eligibility. Surrogate consent will be obtained from the participants legally authorized representative (LAR) by study personnel for eligible patients using remote e-consent process via RedCap. Participants will be randomized 1:1 to receive either early intravenous ketamine plus midazolam infusion or the current institutional protocol of midazolam followed by late ketamine infusion (Fernandez et al., 2018). Continuous video EEG monitoring will guide medication titration, increasing doses every 20 minutes for ongoing seizure activity. The primary goal of this study is to examine the feasibility of the protocol and obtain estimates of the timing of seizure cessation. The primary outcome is time to seizure cessation, defined as the time from initiation of anesthetic infusion (midazolam or midazolam plus ketamine) to the time of last electrographic seizure. The investigators will also collect preliminary data on other clinical measures that would serve as secondary outcomes for future trials. These clinical measures include progression to super refractory status epilepticus, intensive care unit and hospital length of stay, duration of mechanical ventilation, and functional outcomes assessed by the modified Rankin Scale at discharge, 3 months, and 6 months. This study does not evaluate ketamine as a novel therapy but rather assesses a minor modification in the timing of ketamine administration to optimize seizure control.

03

Conditions studied

  • Refractory Status Epilepticus

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults 18 years of age or older
  2. Patients with status epilepticus unresponsive to appropriately dosed agents administered intravenous or intraosseous and one second line agent

    1. First line agents: lorazepam, midazolam, or diazepam
    2. Second line agents: phenytoin (20 mg/kg), valproate (40 mg/kg), levetiracetam (60 mg/kg), lacosamide (400 mg)
  3. All etiologies of status epilepticus will be included

Exclusion criteria

Exclusion Criteria:

  1. Exclusively psychogenic non epileptic seizures
  2. Pregnant individuals
  3. Incarcerated individuals
  4. Patients with to ketamine or any component of the formulation
  5. Conditions in which an increase in blood pressure would be hazardous
  6. Focal motor status epilepticus
  7. Status epilepticus lasting > 24 hours prior to enrollment (SRSE)
  8. Patients with EEG in the ictal-interictal continuum (IIC)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Early ketamine

    Initiation of ketamine infusion simultaneously with midazolam infusion as the third-line anesthetic treatment

    Drug: Ketamine · Drug: Midazolam

  • Active comparator
    Late ketamine

    Initiation of ketamine infusion only after midazolam infusion has been started

    Drug: Ketamine · Drug: Midazolam

Interventions

  • Timing of ketamine initiation will differ between groups (early versus late ketamine)

  • Midazolam infusion will be initiated at the same time in both groups

06

What researchers measure

Primary outcomes

  1. Time to seizure cessation

    Time from initiation of anesthetic infusion (midazolam or midazolam plus ketamine) to the time of last electrographic seizure

    Time frame: 72 hours

07

Study locations

1 site
08

References and documents

Publications

  • Bell ML, Whitehead AL, Julious SA. Guidance for using pilot studies to inform the design of intervention trials with continuous outcomes. Clin Epidemiol. 2018 Jan 18;10:153-157. doi: 10.2147/CLEP.S146397. eCollection 2018. PubMed 29403314 ↗
  • Bruno A, Akinwuntan AE, Lin C, Close B, Davis K, Baute V, Aryal T, Brooks D, Hess DC, Switzer JA, Nichols FT. Simplified modified rankin scale questionnaire: reproducibility over the telephone and validation with quality of life. Stroke. 2011 Aug;42(8):2276-9. doi: 10.1161/STROKEAHA.111.613273. Epub 2011 Jun 16. PubMed 21680905 ↗
  • Golub D, Yanai A, Darzi K, Papadopoulos J, Kaufman B. Potential consequences of high-dose infusion of ketamine for refractory status epilepticus: case reports and systematic literature review. Anaesth Intensive Care. 2018 Sep;46(5):516-528. doi: 10.1177/0310057X1804600514. PubMed 30189827 ↗
  • Janssen PM, Visser NA, Dorhout Mees SM, Klijn CJ, Algra A, Rinkel GJ. Comparison of telephone and face-to-face assessment of the modified Rankin Scale. Cerebrovasc Dis. 2010 Jan;29(2):137-9. doi: 10.1159/000262309. Epub 2009 Dec 1. PubMed 19955737 ↗
  • Legriel S, Oddo M, Brophy GM. What's new in refractory status epilepticus? Intensive Care Med. 2017 Apr;43(4):543-546. doi: 10.1007/s00134-016-4501-6. Epub 2016 Aug 20. No abstract available. PubMed 27544138 ↗
  • Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, Shorvon S, Lowenstein DH. A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015 Oct;56(10):1515-23. doi: 10.1111/epi.13121. Epub 2015 Sep 4. PubMed 26336950 ↗
  • Fletman EW, Cleymaet S, Salvatore A, Devlin K, Pickard A, Shah SO. Ketamine plus midazolam compared to midazolam infusion for the management of refractory status epilepticus. Clin Neurol Neurosurg. 2024 Nov;246:108592. doi: 10.1016/j.clineuro.2024.108592. Epub 2024 Oct 12. PubMed 39418930 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2025; primary completion for Jul 2027, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2025
First posted
Sep 16, 2025
StartEst.
Nov 2025
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2028
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07177235
Responsible party
Syed Omar Shah (Associate Professor, Neurology and Neurological Surgery, Thomas Jefferson University) — Principal investigator
First posted
Sep 16, 2025
Start date
Nov 2025 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Sep 16, 2025

Study contacts

Elizabeth Fletman, DO
Contact
elizabeth.fletman@jefferson.edu
215-955-7000
Syed 0 Shah, MD
Contact
Syed.Shah@Jefferson.edu
Syed O Shah, MD
principal investigator · Thomas Jefferson University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ketamine · Midazolam

Start the discussion